OVID THERAPEUTICS DL-,001 WKN: A2DQ8S ISIN: US6904691010 Kürzel: 1OT Forum: Aktien Thema: Hauptdiskussion

89% Heute

89 %

Die Amis sind noch verhalten

Die Klitsche geht den Bach runter!

Grüner Wochenstart🍀🍀🍀🍀

Jemand hier?

🥂

Etwas zu schnell gewachsen, darum heute kleiner Dämpfer, aber nach wie vor vielversprechendes Investment.

Mahlzeit 😉

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome https://seekingalpha.com/pr/17561466?source=ansh $OVID

191 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-K63EZZ-31269 9 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=ovid+therapeutics+&cntry=&state=&city=&dist=

Cash: 37.9mio$ burn: 3.2mio$/month reicht in Zusammenhang mit dem Oktober Offering bis Mitte 2021 Proforma cash of ~$71M(1); fully funded through clinical data events PRICE TO BOOK 5.71 MARKET CAP 172,139,162 SHARES 47,816,434 AV. DAILY VOLUME 721,785

RBC Capital analyst Brian Abrahams sees a favorable risk-reward for Ovid Therapeutics (NASDAQ:OVID) heading into next year. The key data catalysts will be for lead programs OV101 and soticlestat. Data for OV101 for FXS should report in Q1, and the pivotal Phase 3 trial for Angelman's Syndrome will report in mid-2020. Abrahams says "there are underappreciated signals of efficacy" for the latter indication that could provide a "low regulatory bar" for the disease. The analyst thinks OV101 could generate $450M+ in "peak annual out-year revenue if successful." For soticlestat, he sees a near $400M out-year sales opportunity for refractory epilepsies. RBC maintains an Outperform rating and $12 price target. OVID has a Very Bullish average Sell Side rating.

OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020 Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET Non-Interventional Data in Fragile X Expected by Early Q2 2020 OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE): Data from Randomized Phase 2 ELEKTRA Trial in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Expected in 2H 2020 Initial Data from Phase 2 ARCADE Trial in Dup15q Syndrome or CDKL5 Deficiency Disorder Expected in Q1 2020 Additional Clinical Data From ENDYMION Open Label Extension Study Expected in Q1 2020

Watchlist aufgenommen